Almost every patient I meet for a cancer consultation asks the same question — sometimes within the first five minutes: "Doctor, should I have robotic surgery or open surgery?" This article gives the honest, evidence-based answer that I share in my consulting room every day.
The robotic surgery debate generates strong opinions on both sides. Marketing material from hospitals often overstates robotic benefits. Older surgeons sometimes dismiss it as "fancy laparoscopy with a price tag." Both positions miss the point.
What matters is what the high-quality clinical trials actually show — and what they show is more nuanced than either camp wants to admit. Let me walk you through the evidence, then tell you what I think it means for patients facing real surgical decisions.
- Understanding the Technology — What Robotic Surgery Actually Is
- The Evidence — Five Trials Every Patient Should Know
- The Real Clinical Differences — Side by Side
- Where Robotic Surgery Clearly Wins
- Where Open Surgery Still Has Its Place
- By Cancer Type — A Practical Guide
- The Cost Question — Is It Worth Paying More?
- The Bottom Line — A Surgeon's Honest Take
Understanding the Technology — What Robotic Surgery Actually Is
The Da Vinci Surgical System — the dominant robotic platform globally — is not an autonomous robot. The surgeon controls every movement from a console a few feet away from the patient. Four robotic arms hold instruments and a 3D high-definition camera inserted through small (8 mm) ports.
The key technological advantages over open or laparoscopic surgery come from three engineered features:
- 10x magnified 3D vision — the surgeon sees anatomy at higher resolution than the naked eye allows, with true depth perception that traditional laparoscopy lacks.
- Wristed instrumentation — the robotic instruments have seven degrees of freedom, mimicking the human wrist. Conventional laparoscopic tools have only four. This matters in narrow spaces like the deep pelvis.
- Tremor filtration and motion scaling — even an experienced surgeon's hand has micro-tremor. The robot filters this out and can scale movements down (5 mm of hand movement becomes 1 mm of instrument movement) for precision in delicate dissections.
None of this replaces surgical skill. It extends it. A surgeon who can't perform an operation well by open surgery will not magically do it well robotically. But a skilled surgeon equipped with the robot can do certain operations more precisely than would be possible with their hands alone.
The Evidence — Five Trials Every Patient Should Know
Many things in surgery are claimed but few are proven. These five randomised trials are the foundation of what we actually know about robotic versus open and laparoscopic approaches for cancer surgery.
The first large randomised trial comparing robotic and laparoscopic resection for rectal cancer. The primary endpoint was conversion to open surgery — a marker of how often the minimally invasive approach fails mid-operation.
The largest robotic rectal cancer trial ever conducted, with a primary endpoint of 3-year disease-free survival — the outcome that actually matters for patients.
While not specifically a robotic trial, COLOR II established the benchmark for minimally invasive rectal cancer surgery — laparoscopic surgery achieved equivalent 3-year disease-free survival to open with significantly faster recovery. This study made robust the case that minimally invasive surgery, in expert hands, is safe for rectal cancer — paving the way for the robotic trials that followed.
Robot-assisted minimally invasive oesophagectomy versus open transthoracic oesophagectomy for resectable oesophageal cancer.
Not every minimally invasive operation is automatically better. LACC compared open versus minimally invasive radical hysterectomy (laparoscopic or robotic) for early-stage cervical cancer. Disease-free survival at 4.5 years was significantly worse with minimally invasive surgery (86.0% vs 96.5%).
The Real Clinical Differences — Side by Side
The following comparison synthesises outcomes data across multiple trials and meta-analyses (Brar et al., 2023; Solaini et al., 2022; Park et al., 2021). These are averages — individual patient experiences vary, and the absolute differences depend heavily on the specific cancer and surgeon experience.
| Outcome | Robotic Surgery | Open Surgery |
|---|---|---|
| Average blood loss | 100–200 ml | 400–700 ml |
| Operative time | Longer (15–60 min more) | Shorter |
| Hospital stay | 3–5 days | 7–12 days |
| Post-operative pain | Significantly less | Moderate to severe |
| Wound infection rate | 2–4% | 8–15% |
| Return to normal activity | 2–4 weeks | 6–10 weeks |
| Scar size | 3–4 cm total (multiple ports) | 15–30 cm single scar |
| Lymph node yield | Equivalent | Equivalent |
| Surgical margin clearance | Equivalent or better | Standard |
| 5-year survival | Equivalent (most cancers) | Equivalent |
| Surgeon ergonomics | Excellent (seated console) | Demanding (standing, leaning) |
| Tactile feedback | Limited | Full |
| Cost (Indian context) | ₹2.5–5 lakh additional | Lower baseline |
| Availability | Tertiary centres only | Widely available |
Where Robotic Surgery Clearly Wins
There are anatomical and clinical scenarios where the evidence for robotic surgery is now strong enough that I recommend it as the first choice when available and affordable:
- Low rectal cancer (deep pelvis access)
- Sphincter preservation surgery
- Oesophageal cancer resection
- Whipple (pancreaticoduodenectomy)
- Obese patients (any cancer)
- Prostate cancer (now standard of care)
- Robotic thyroidectomy (scarless)
- Renal partial nephrectomy
- Adrenal tumour resection
- Complex liver resections
- Early-stage cervical cancer (LACC evidence)
- Very large, locally advanced tumours
- Tumours invading major blood vessels
- Emergency cancer surgery
- Patients unfit for prolonged pneumoperitoneum
- Re-do surgeries with dense adhesions
- Patients with severe heart/lung disease
- Where robotic platform unavailable
- Resource-limited settings
- Surgeon strongly prefers open for safety
The Pelvic Advantage
The single biggest robotic advantage is access to the deep, narrow pelvis — where a surgeon's hand and laparoscopic instruments alike struggle. For rectal cancer in particular, the robotic platform's wristed instruments and 3D visualisation allow far better dissection of the mesorectum, preservation of pelvic autonomic nerves (which protect urinary and sexual function), and clearance close to vital structures.
This is why the REAL trial showed improved disease-free survival with robotic rectal surgery — and why I have moved almost entirely to robotic for rectal cancer in suitable patients.
The Ergonomic Reality
A point rarely discussed in patient consultations: surgeons who operate from a seated console with magnified vision and tremor filtration perform better as the operation goes on. Open surgery — especially for long pelvic or upper-abdominal cases — leaves the surgeon physically fatigued by hour four. A fatigued surgeon makes more mistakes. Robotic surgery, paradoxically, can be safer for complex long operations partly because it keeps the surgeon fresh.
Where Open Surgery Still Has Its Place
I still perform open surgery regularly. It would be irresponsible to suggest otherwise. The situations where open surgery is the right choice include:
1. Locally advanced disease with vascular invasion. When a tumour involves the inferior vena cava, the portal vein, or the aorta, the tactile feedback and large working space of open surgery is genuinely safer. The robot's lack of haptic feedback becomes a real disadvantage.
2. Emergencies. A perforated colon cancer, a bleeding tumour, an acute obstruction — these need decisive action. The 30–45 minutes required to dock a robot is time the patient may not have.
3. Cervical cancer (early stage). The LACC trial result was unexpected and remains controversial, but until we understand why minimally invasive surgery worsened outcomes in this specific setting, open radical hysterectomy is the safer choice for women with early-stage cervical cancer.
4. Cost-constrained patients. If the difference between robotic and open is the difference between affording cancer treatment and not affording it, open surgery in expert hands is excellent and well-validated treatment. I have never told a patient that their cancer was less curable because they had open surgery.
By Cancer Type — A Practical Guide
| Cancer | Preferred Approach | Evidence Quality |
|---|---|---|
| Rectal cancer | Robotic (when available) | REAL trial — strong |
| Colon cancer | Robotic or laparoscopic equivalent | Multiple RCTs |
| Oesophageal cancer | Robotic | ROBOT trial — strong |
| Pancreatic cancer (Whipple) | Robotic emerging | Moderate; institutional |
| Stomach cancer | Robotic or laparoscopic | Multiple meta-analyses |
| Liver tumours | Robotic for selected cases | Moderate |
| Prostate cancer | Robotic (gold standard) | Strong, established |
| Kidney (partial) | Robotic preferred | Strong |
| Cervical cancer (early) | Open (LACC evidence) | Strong, surprising |
| Endometrial cancer | Robotic or laparoscopic | LAP-2 trial |
| Ovarian cancer | Open for advanced disease | Strong consensus |
| Thyroid cancer | Open or robotic (cosmetic) | Equivalent oncology |
| Breast cancer | Robotic emerging for nipple-sparing mastectomy | Early evidence |
| Lung cancer (early) | Robotic or VATS | Multiple RCTs |
The Cost Question — Is It Worth Paying More?
In India, the additional cost of robotic surgery typically ranges from ₹2.5 to ₹5 lakh over open surgery, depending on the procedure and hospital. This is a substantial sum for most families. The honest answer to "is it worth it" depends on three factors:
1. The specific operation. For low rectal cancer in an obese man, the answer is increasingly clear — yes. For an easy hemicolectomy in a thin patient, the marginal benefit may not justify the cost. The evidence does not support paying premium for robotic surgery in every situation.
2. The patient's recovery priorities. A 35-year-old breadwinner who needs to return to work fast may rationally choose to pay more for the 4-week recovery advantage. A 75-year-old retired patient with grandchildren to enjoy may make the same choice for different reasons. A patient where every rupee matters for adjuvant chemotherapy needs the savings.
3. Insurance coverage. Many insurance policies in India now cover robotic surgery — sometimes fully, sometimes with co-pay. Check your policy. The financial calculation changes substantially if covered.
What I tell my patients
"Robotic surgery is not the only way to cure your cancer. It is one of the best ways, when properly indicated. If you can afford it and it is suitable for your cancer, choose it. If you cannot, do not feel you are getting second-best care — open surgery in experienced hands has cured cancer patients for over a century, and continues to do so very well."
The Bottom Line — A Surgeon's Honest Take
After 30 years of cancer surgery — first open, then laparoscopic, and now increasingly robotic — here is what I believe the evidence actually supports:
Robotic surgery is genuinely better for some operations. Rectal cancer in the deep pelvis, oesophageal resection, prostate cancer, and partial nephrectomy are now situations where robotic offers measurable advantages in outcomes that matter to patients — recovery, function preservation, and in some cases, oncological clearance.
Robotic surgery is equivalent (not superior) for many operations. Colon cancer, stomach cancer, endometrial cancer, lung cancer — the oncological outcomes are the same as open or laparoscopic. Patients pay extra primarily for recovery benefits, not survival benefits.
Robotic surgery is occasionally worse. Early-stage cervical cancer is the clearest example. Locally advanced disease invading major vessels is another. A good surgical oncologist recognises these and recommends open surgery without ego.
What matters more than robotic vs open is who is operating. A surgeon who performs 100+ robotic cancer cases a year will achieve better outcomes with the robot than a surgeon doing 20. A master open surgeon will achieve better outcomes with open surgery than an inexperienced robotic surgeon will with the machine. Choose the surgeon first, the approach second.
Questions Worth Asking Your Surgeon
If you are considering robotic versus open surgery, these are the questions I'd want a patient to ask:
- How many robotic cases do you do per year for my specific cancer?
- What is your conversion rate from robotic to open?
- What evidence supports robotic over open for my specific cancer and stage?
- What is the difference in your hands — recovery, complications, oncological outcomes?
- If money were no object, what would you recommend? If money is the constraint, what would you recommend?
- Are there features of my specific case (size, location, prior surgery, BMI) that change your recommendation?
A surgeon who answers these clearly, with reference to evidence rather than marketing, is the one to trust.
Considering Robotic Cancer Surgery in Pune?
Dr. Vinod T. Gore performs both open and robotic cancer surgery and will give you an honest, evidence-based recommendation for your specific situation — including when robotic is NOT the right choice. Bring all scans and biopsy reports for a complete assessment at Silver Leaf Clinic, Hadapsar.
About the Author: Dr. Vinod T. Gore is a Senior Surgical Oncologist with over 30 years of experience. Trained at Tata Memorial Hospital Mumbai (5-year residency + thoracic, breast oncoplastic, and head & neck fellowships) and FARIS Edinburgh (Advanced Robotic Surgery). Recipient of the ET Onco Frontiers Trailblazer in Oncology 2025 and Navbharat Times Best Robotic Oncosurgeon 2024. Department Head of Surgical Oncology at Sahyadri Manipal Hospital, Pune, and practices at Silver Leaf Clinic, Hadapsar.
Medical Disclaimer: This article is for educational purposes and does not constitute medical advice. Surgical decisions are highly individual. Please consult a qualified surgical oncologist for guidance specific to your case.
References: Jayne D et al. JAMA 2017 (ROLARR); Feng Q et al. Lancet Gastroenterol Hepatol 2022 (REAL); Bonjer HJ et al. NEJM 2015 (COLOR II); van der Sluis PC et al. Ann Surg 2019 (ROBOT); Ramirez PT et al. NEJM 2018 (LACC); Brar SS et al. Ann Surg Oncol 2023 (meta-analysis); Solaini L et al. Surg Endosc 2022 (meta-analysis).